AVGR:NSD-Avinger, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.99

Change

-0.14 (-6.57)%

Market Cap

USD 0.18B

Volume

0.02B

Average Target Price

USD 1.75 (-12.06%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California. Address: 400 Chesapeake Drive, Redwood City, CA, United States, 94063

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+5.39 (+1.01%)

USD42.11B 24.30 100.03
PODD Insulet Corporation

-1.39 (-0.48%)

USD19.14B 659.77 158.47
ABMD Abiomed, Inc

+0.42 (+0.12%)

USD15.72B 76.46 61.68
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.74 (-1.22%)

USD9.32B 60.12 28.92
TNDM Tandem Diabetes Care, Inc

+1.86 (+1.89%)

USD6.13B N/A N/A
IART Integra LifeSciences Holdings ..

+0.06 (+0.09%)

USD5.84B 105.00 26.55
SWAV ShockWave Medical, Inc

-2.03 (-1.56%)

USD4.45B N/A N/A
SDC SmileDirectClub, Inc

+2.30 (+20.80%)

USD4.27B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing AVGR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 352.17% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 352.17% 100% A+ 100% A+
Trailing 12 Months  
Capital Gain 127.17% 90% A- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 127.17% 90% A- 86% B
Trailing 5 Years  
Capital Gain -99.97% 6% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.97% 6% F N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -82.31% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.31% 1% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.10% 88% B+ 69% D+
Risk Adjusted Return -409.51% 1% F N/A N/A
Market Capitalization 0.18B 39% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.09 82% B- 92% A-
Price/Book Ratio 3.82 67% D+ 43% F
Price / Cash Flow Ratio -10.48 56% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -168.02% 14% F 6% F
Return on Invested Capital -118.01% 20% F 7% F
Return on Assets -34.99% 21% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.05 99% A+ 97% A+
Short Percent 1.33% 91% A- 73% C
Beta 2.01 14% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector